SCHEMBL1355881

SCHEMBL1355881

c1ccc(-c2ccccc2-n2ncc3cnc(Nc4ccc(N5CCOCC5)cc4)nc32)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT6 P42226 6/20 0.57
JAK2 O60674 3/20 0.54
JUN P05412 1/20 0.54
MAPK8 P45983 1/20 0.54
MAPK10 P53779 1/20 0.54
IGF1R P08069 1/20 0.53
CDK4 P11802 3/20 0.51
CCND3 P30281 3/20 0.51
CCND1 P24385 2/20 0.51
CCND2 P30279 2/20 0.51
AURKA O14965 2/20 0.51
INSR P06213 1/20 0.50
PLK4 O00444 1/20 0.50
CCNA2 P20248 2/20 0.49
CDK2 P24941 2/20 0.49
JAK3 P52333 2/20 0.49
PTK2 Q05397 2/20 0.49
CCNB2 O95067 1/20 0.49
CCNE2 O96020 1/20 0.49
CDK1 P06493 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1353840 0.89 CDK4 (0.54) STAT6JAK2MAPK8MAPK10CDK4
SCHEMBL1355286 0.89 CDK4 (0.59) JAK2CDK4CCND3CCND1CCND2
SCHEMBL3585927 0.85 STAT6 (0.53) STAT6JAK2IGF1RCDK4CCND3
SCHEMBL1356073 0.82 STAT6 (0.50) STAT6JAK2JUNMAPK8MAPK10
SCHEMBL1353745 0.80 AURKA (0.53) JAK2AURKAAURKB
SCHEMBL1355600 0.79 SYK (0.54) STAT6IGF1RCDK4CCND3CCND1
SCHEMBL16513631 0.79 MAPK10 (0.79) STAT6JAK2JUNMAPK8MAPK10
SCHEMBL29847439 0.79 MAPK10 (0.79) STAT6JAK2JUNMAPK8MAPK10
SCHEMBL3583463 0.78 CDK4 (0.52) STAT6JAK2IGF1RCDK4CCND3
SCHEMBL1353795 0.78 DCLK1 (0.52) CDK4CCND3CCND1CCND2AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110281821-A9 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2011-11-17 US claimed
US-20100249067-A1 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2010-09-30 US claimed
US-20110281821-A9 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2011-11-17 US disclosed
US-20100249067-A1 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2010-09-30 US disclosed
EP-2108020-A2 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES Biogen Idec MA, Inc. (US) 2009-10-14 EP disclosed
WO-2008094602-A2 1-H-PYRAZOLO (3,4B) PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES BIOGEN IDEC MA INC. (US) 2008-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249067-A1 Modulators of Mitotic Kinases BUB1, BUB1B, CDK1 STAT6 2214/4885JAK2 1365/4885JUN 1898/4885
US-20110281821-A9 Modulators of Mitotic Kinases BUB1, BUB1B, CDK1 STAT6 2214/4885JAK2 1365/4885JUN 1898/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.